News

A recent study published in Blood identifies soluble BCMA (sBCMA) levels and metabolic tumor volume (MTV) as potential biomarkers for predicting CAR-T therapy outcomes in relapsed and refractory multiple myeloma (RRMM) patients, paving the way for personalized treatment strategies.

CAR-T therapy, originally a breakthrough for B-cell malignancies, is showing promise in treating T-cell lymphomas and T-cell acute lymphoblastic leukemia (T-ALL). This evolving treatment faces unique challenges but recent clinical trials offer hope for new therapeutic solutions in T-cell malignancies.

The Lu Daopei Medical Team achieves a groundbreaking advancement in treating Acute Myeloid Leukemia (AML) with their study on nanobody-based CD7 CAR-T therapy, published in the prestigious journal Blood.

Recent advancements in Menin inhibitors offer promising treatment options for acute myeloid leukemia (AML), targeting genetic mutations and providing new hope for challenging cases.

At the 2024 ASH Annual Meeting, Professor Sun Yuqian shared his groundbreaking research on breakthrough invasive fungal disease (bIFD) in patients with hematologic malignancies, highlighting diagnostic and therapeutic challenges, as well as practical insights based on recent studies.

A new study published in Blood refines the risk stratification for T-cell acute lymphoblastic leukemia (T-ALL) using next-generation sequencing (NGS), enhancing prognosis predictions and identifying high-risk subgroups that could benefit from targeted therapies.

A recent study published in Nature Cancer highlights the long-term complications of CAR-T cell therapy, focusing on the risks of infections and secondary malignancies, and offers strategies to optimize patient outcomes.

The Lu Daopei Medical Team, led by Dr. Cao Xingyu and Prof. Lu Peihua, has published an important clinical research paper in the British Journal of Haematology (Impact Factor 5.1). The study investigates the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) after autologous CD7 CAR-T therapy for refractory and relapsed T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (R/R T-ALL/T-LBL).

A moving patient story from Lu Daopei Hospital, highlighting the journey of a 32-year-old male AML-M2 survivor who, after undergoing haploidentical stem cell transplantation, celebrates 9 years of remission, living a full and vibrant life, fueled by love, hope, and resilience.

A study presented at ASH 2024 by Dr. Zhi-Jie Wei and his team at Lu Daopei Hospital highlights the effectiveness of modified Bu/Cy-based regimens in haploidentical hematopoietic stem cell transplantation for Non-Down Syndrome Acute Megakaryoblastic Leukemia (AMKL), showing promising survival outcomes for complete remission (CR) patients.

At the 2024 ASH Annual Meeting, Prof. Lu Peihua from Lu Daopei Hospital presented groundbreaking results from a Phase I trial of CD7 CAR-T cell therapy for relapsed/refractory peripheral T-cell lymphoma (R/R PTCL), showing promising efficacy and manageable safety.

While CAR-T therapy has revolutionized the treatment of B-cell cancers, significant challenges remain in treating T-cell malignancies. A recent review explores the complexities of CAR-T therapy in T-cell blood cancers and potential solutions to overcome these obstacles.